GENERALIZED MYASTHENIA GRAVIS
Clinical trials for GENERALIZED MYASTHENIA GRAVIS explained in plain language.
Never miss a new study
Get alerted when new GENERALIZED MYASTHENIA GRAVIS trials appear
Sign up with your email to follow new studies for GENERALIZED MYASTHENIA GRAVIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for chinese MG patients: ravulizumab trial targets daily symptom relief
Disease control Not yet recruitingThis study tests a drug called ravulizumab in 20 Chinese adults with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The goal is to see if the drug improves daily activities and muscle strength over 26 weeks. Participants must have a specific antibod…
Matched conditions: GENERALIZED MYASTHENIA GRAVIS
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 08:57 UTC
-
New drug rozanolixizumab under Real-World watch for muscle weakness
Disease control Not yet recruitingThis study tracks 50 adults with generalized myasthenia gravis (a rare autoimmune disease causing muscle weakness) who are taking Rozanolixizumab. Researchers want to see how symptoms change from the patient's perspective using a special questionnaire. The study is observational,…
Matched conditions: GENERALIZED MYASTHENIA GRAVIS
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New cell therapy trial aims to tame muscle weakness in rare disease
Disease control Not yet recruitingThis early study tests a new treatment called HN2301 in 6 adults with generalized myasthenia gravis, a disease that causes muscle weakness. The treatment uses modified immune cells (CAR-T cells) to target and reduce harmful antibodies. The main goal is to check safety and see how…
Matched conditions: GENERALIZED MYASTHENIA GRAVIS
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated May 22, 2026 13:51 UTC